Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating restated by investment analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Friday. They currently have a $203.00 price target on the medical research company’s stock. Oppenheimer Holdings, Inc.’s price objective suggests a potential upside of 8.66% from the company’s current price.

Several other research firms have also commented on AMGN. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 26th. Mizuho reiterated a “buy” rating and issued a $198.00 target price (up from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, Argus lifted their target price on Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a report on Thursday, July 27th. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and an average target price of $189.99.

Shares of Amgen (AMGN) traded down 0.5189% during midday trading on Friday, reaching $185.8804. The company’s stock had a trading volume of 1,076,828 shares. Amgen has a one year low of $133.64 and a one year high of $191.10. The stock’s 50-day moving average is $180.82 and its 200-day moving average is $170.11. The company has a market capitalization of $135.63 billion, a P/E ratio of 16.9305 and a beta of 1.36. Amgen also was the target of unusually large options trading on Thursday. Stock traders bought 9,350 put options on the stock. This represents an increase of 239% compared to the average daily volume of 2,758 put options.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the business posted $2.84 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts expect that Amgen will post $12.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Amgen’s (AMGN) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc.” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/06/amgens-amgn-buy-rating-reaffirmed-at-oppenheimer-holdings-inc.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Camelot Portfolios LLC acquired a new stake in shares of Amgen during the first quarter worth about $1,429,000. PGGM Investments increased its position in shares of Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares in the last quarter. Shelton Capital Management increased its position in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares in the last quarter. Greylin Investment Mangement Inc. increased its position in shares of Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares in the last quarter. Finally, Kelman Lazarov Inc. increased its position in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after purchasing an additional 120 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.